Please check your internet connection and try again.
# Ecospirin (Aspirin, Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of acetylsalicylic acid (ASA), formulated to reduce direct gastric mucosal irritation by delaying dissolution until the tablet reaches the small intestine. It acts as an irreversible inhibitor of cyclooxygenase (COX-1 and COX-2) enzymes.
## Primary Indications
* **Antiplatelet:** Secondary prevention of myocardial infarction (MI), ischemic stroke, and transient ischemic attacks (TIA).
* **Acute Coronary Syndrome (ACS):** Initial management of suspected acute MI.
* **Chronic management:** Stable/unstable angina and post-revascularization procedures (PCI/CABG).
## Adult Dosing
* **Secondary Prevention/Maintenance:** 75 mg to 325 mg orally once daily. (Low-dose [75-100 mg] is standard for long-term antiplatelet therapy to minimize bleeding risk).
* **Acute Coronary Syndrome:** 160 mg to 325 mg (non-enteric coated preferred for initial dose if available for rapid absorption; if only enteric-coated is available, tablet should be chewed).
## Pediatric Dosing
* **Kawasaki Disease (Acute Phase):** 80–100 mg/kg/day divided every 6 hours (up to 4 g/day) under strict rheumatology/cardiology supervision.
* **Kawasaki Disease (Maintenance/Antiplatelet):** 3–5 mg/kg/day once daily.
* **Note:** Use in children for viral symptoms is **strictly contraindicated** due to the high risk of Reye's syndrome.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Generally avoid in severe renal failure (CrCl < 10 mL/min).
* **Hepatic Impairment:** Use with caution; monitor for increased bleeding risk and hepatotoxicity.
## Contraindications
* Hypersensitivity to salicylates or NSAIDs.
* Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage).
* Asthma associated with nasal polyps (risk of severe bronchospasm).
* Children and adolescents recovering from viral infections (risk of Reye's syndrome).
* Pregnancy (third trimester).
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, gastric ulceration, gastrointestinal hemorrhage.
* **Hematologic:** Increased bleeding time, epistaxis, bruising.
* **Other:** Tinnitus (sign of salicylate toxicity), bronchospasm, hypersensitivity reactions.
## Key Drug Interactions
* **Anticoagulants/Antiplatelets (e.g., Warfarin, Clopidogrel, Apixaban):** Significant increase in additive bleeding risk.
* **NSAIDs (e.g., Ibuprofen):** May interfere with the antiplatelet effect of low-dose aspirin; space doses appropriately (Ibuprofen taken ≥8 hours before or ≥30 minutes after aspirin).
* **Corticosteroids:** Increased risk of GI ulceration.
## Monitoring
* **Clinical:** Watch for signs of unexplained bruising, melena, or hematemesis.
* **Laboratory:** Consider baseline and periodic CBC (hemoglobin/hematocrit) in patients on long-term therapy.
* **Toxicity:** Monitor for tinnitus, hearing loss, or metabolic acidosis if high-dose therapy is used.
## Clinical Pearls
* **Enteric coating delay:** Enteric-coated formulations are not suitable for the initial loading dose in ACS because they do not dissolve reliably for rapid systemic absorption. If only enteric-coated aspirin is available for an acute MI, crush or chew the tablet to bypass the coating.
* **Adherence:** Do not crush or split enteric-coated tablets unless specific instructions allow, as this destroys the delayed-release mechanism.
* **Local Protocols:** Institutional protocols for perioperative management or specific cardiology pathways may dictate exact dosing titration; always verify local guidelines.
***
*Disclaimer: This information is for educational purposes only. Prescribing practices and clinical protocols vary by institution and patient-specific factors. Always consult the most recent product monograph and verified clinical guidelines before prescribing or administering medication.*
